9,252 results on '"Saag A"'
Search Results
2. Changes in the Workforce Characteristics of Providers Who Care for Adult Patients With Rheumatologic and Musculoskeletal Disease in the United States
- Author
-
Mannion, Melissa L, Xie, Fenglong, FitzGerald, John D, Alexander, Amanda, Mudano, Amy, Su, Yujie, Saag, Kenneth G, and Curtis, Jeffrey R
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Autoimmune Disease ,Arthritis ,8.1 Organisation and delivery of services ,Health and social care services research - Abstract
ObjectiveThe aim of this study was to describe the adult rheumatology workforce in the United States, assess change in rheumatology providers over time, and identify variation in rheumatology practice characteristics.MethodsUsing national Medicare claims data from 2006 to 2020, clinically active rheumatology physicians and advanced practice providers (APPs) were identified. Each calendar year was used for inclusion, exclusion, and analysis, and providers were determined to be entering, exiting, or stable based upon presence or absence in the prior or subsequent years of data. Characteristics (age, gender, practice type, rural, and region) of rheumatologists were determined for 2019 and in mutually exclusive study periods from 2009 to 2011, 2012 to 2015, and 2016 to 2019. The location of rheumatology practice was determined by billing tax identification and mapped. Demographics of physicians exiting or entering the rheumatology workforce were compared separately to those stable by logistic regression.ResultsThe clinically active adult rheumatology workforce identified in US Medicare in 2019 was 5,667 rheumatologists and 379 APPs. From 2009 to 2020, the number of rheumatologists increased 23% and the number of APPs increased 141%. There was an increase in female rheumatologists over time, rising to 43% in 2019. Women and those employed by a health care system were more likely to exit, and those in a small practice or in the South were less likely to exit.ConclusionThe overall number of clinically active rheumatology providers grew more than 20% over the last decade to a high of 6,036 in 2020, although this rate of growth appears to be flattening off in later years.
- Published
- 2024
3. Association of Alcohol Use with COVID-19 Infection and Hospitalization Among People Living with HIV in the United States, 2020
- Author
-
Xia, Chunyi, Chander, Geetanjali, Hutton, Heidi E., McCaul, Mary E., Delaney, Joseph A., Mayer, Kenneth H., Jacobson, Jeffrey M., Puryear, Sarah, Crane, Heidi M., Shapiro, Adrienne E., Cachay, Edward R., Lau, Bryan, Napravnik, Sonia, Saag, Michael, and Lesko, Catherine R.
- Published
- 2024
- Full Text
- View/download PDF
4. Plants, fungi, and carabid beetles in temperate forests: both observed and dark diversity depend on habitat availability in space and time
- Author
-
Riibak, Kersti, Noreika, Norbertas, Helm, Aveliina, Öpik, Maarja, Kook, Ene, Kasari-Toussaint, Liis, Jõks, Madli, Paganeli, Bruno, Zárate Martínez, Oscar, Tullus, Hardi, Tullus, Tea, Lutter, Reimo, Oja, Ede, Saag, Andres, Randlane, Tiina, and Pärtel, Meelis
- Published
- 2024
- Full Text
- View/download PDF
5. Biological and Clinical Implications of the Vascular Endothelial Growth Factor Coreceptor Neuropilin-1 in Human Immunodeficiency Virus
- Author
-
Schnittman, Samuel R, Kolossváry, Márton, Beck-Engeser, Gabriele, Fitch, Kathleen V, Ambayec, Gabrielle C, Nance, Robin M, Zanni, Markella V, Diggs, Marissa, Chan, Fay, McCallum, Sara, Toribio, Mabel, Bamford, Laura, Fichtenbaum, Carl J, Eron, Joseph J, Jacobson, Jeffrey M, Mayer, Kenneth H, Malvestutto, Carlos, Bloomfield, Gerald S, Moore, Richard D, Umbleja, Triin, Saag, Michael S, Aberg, Judith A, Currier, Judith S, Delaney, Joseph AC, Martin, Jeffrey N, Lu, Michael T, Douglas, Pamela S, Ribaudo, Heather J, Crane, Heidi M, Hunt, Peter W, and Grinspoon, Steven K
- Subjects
Biomedical and Clinical Sciences ,Immunology ,Heart Disease ,HIV/AIDS ,Infectious Diseases ,Aging ,Sexually Transmitted Infections ,Heart Disease - Coronary Heart Disease ,Prevention ,Cardiovascular ,2.1 Biological and endogenous factors ,Aetiology ,Cancer ,Good Health and Well Being ,cancer ,cardiovascular disease ,HIV ,neuropilin-1 ,VEGF ,Clinical sciences ,Medical microbiology - Abstract
Plasma vascular endothelial growth factor (VEGF) coreceptor neuropilin-1 (NRP-1) had the largest association with coronary plaque in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) proteomics analysis. With little known about NRP-1 in people with human immunodeficiency virus (PWH), we explored its relation to other proteins in REPRIEVE and validated our findings through a Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) case-cohort study by assessing its relation to host factors and incident cardiovascular disease and cancer. Within REPRIEVE, NRP-1 was associated with proteins involved in angiogenesis, signal transduction, immunoregulation, and cell migration/adhesion. Within CNICS, NRP-1 was associated with key host factors, including older age and male sex. NRP-1 was associated with an increased hazard of multiple cancers but a decreased prostate cancer risk. Finally, NRP-1 was most strongly associated with mortality and type 2 myocardial infarction. These data suggest that NRP-1 is part of a clinically relevant immunoregulatory pathway related to multiple comorbidities in PWH. Clinical Trials Registration. NCT02344290.
- Published
- 2023
6. Polygenic risk scores point toward potential genetic mechanisms of type 2 myocardial infarction in people with HIV.
- Author
-
Lee, Won, Cheng, Haoxiang, Whitney, Bridget, Nance, Robin, Britton, Sierra, Jordahl, Kristina, Lindstrom, Sara, Ruderman, Stephanie, Kitahata, Mari, Saag, Michael, Willig, Amanda, Burkholder, Greer, Eron, Joseph, Kovacic, Jason, Björkegren, Johan, Mathews, W, Cachay, Edward, Feinstein, Matthew, Budoff, Mathew, Hunt, Peter, Moore, Richard, Keruly, Jeanne, McCaul, Mary, Chander, Geetanjali, Webel, Allison, Mayer, Kenneth, Delaney, Joseph, Crane, Paul, Martinez, Claudia, Crane, Heidi, Hao, Ke, and Peter, Inga
- Subjects
Energy metabolism ,HIV ,Polygenic risk score ,Type 1 myocardial infarction ,Type 2 myocardial infarction ,Humans ,Myocardial Infarction ,Risk Factors ,Anterior Wall Myocardial Infarction ,HIV Infections ,Myocardium - Abstract
BACKGROUND: People with human immunodeficiency virus (HIV) infection (PWH) are at higher risk of myocardial infarction (MI) than those without HIV. About half of MIs in PWH are type 2 (T2MI), resulting from mismatch between myocardial oxygen supply and demand, in contrast to type 1 MI (T1MI), which is due to primary plaque rupture or coronary thrombosis. Despite worse survival and rising incidence in the general population, evidence-based treatment recommendations for T2MI are lacking. We used polygenic risk scores (PRS) to explore genetic mechanisms of T2MI compared to T1MI in PWH. METHODS: We derived 115 PRS for MI-related traits in 9541 PWH enrolled in the Centers for AIDS Research Network of Integrated Clinical Systems cohort with adjudicated T1MI and T2MI. We applied multivariate logistic regression analyses to determine the association with T1MI and T2MI. Based on initial findings, we performed gene set enrichment analysis of the top variants composing PRS associated with T2MI. RESULTS: We found that T1MI was strongly associated with PRS for cardiovascular disease, lipid profiles, and metabolic traits. In contrast, PRS for alcohol dependence and cholecystitis, significantly enriched in energy metabolism pathways, were predictive of T2MI risk. The association remained after the adjustment for actual alcohol consumption. CONCLUSIONS: We demonstrate distinct genetic traits associated with T1MI and T2MI among PWH further highlighting their etiological differences and supporting the role of energy regulation in T2MI pathogenesis.
- Published
- 2023
7. 20 Turning Research Results into Clinical Practice Guidelines in Public Health Emergencies
- Author
-
Jacobsen, Donna M., Masur, Henry, Saag, Michael S., Volberding, Paul A., Sorenson, Robert A., editor, Higgs, Elizabeth S., Editor-in-Chief, Fallah, Mosoka P., Section Editor, Lurie, Nicole, Section Editor, McNay, Laura A., Section Editor, and Smith, Peter G., Section Editor
- Published
- 2024
- Full Text
- View/download PDF
8. The effect of cystic echinococcosis (hydatid disease) on carcase weight in cattle in eastern Australia
- Author
-
Brookes, Victoria J., Barnes, Tamsin S., Jenkins, David J., Van der Saag, Matthew R., Dempster, Robert, and Wilson, Cara S.
- Published
- 2024
- Full Text
- View/download PDF
9. Associations between alcohol and cigarette use and type 1 and 2 myocardial infarction among people with HIV.
- Author
-
Drumright, Lydia, Nance, Robin, Ruderman, Stephanie, Ma, Jimmy, Whitney, Bridget, Hahn, Andrew, Fredericksen, Rob, Luu, Brandon, Lober, William, Moore, Richard, Budoff, Matthew, Keruly, Jeanne, Christopoulos, Katerina, Puryear, Sarah, Willig, Amanda, Cropsey, Karen, Mathews, Christopher, Cachay, Edward, Bamford, Laura, Eron, Joseph, Napravnik, Sonia, Mayer, Kenneth, OCleirigh, Conall, Mccaul, Mary, Chander, Geetanjali, Feinstein, Matthew, Saag, Michael, Kitahata, Mari, Heckbert, Susan, Crane, Heidi, and Delaney, Joseph
- Subjects
HIV ,alcohol use ,binge drinking ,people with HIV ,smoking ,type 1 myocardial infarction ,type 2 myocardial infarction ,Male ,Humans ,Female ,HIV Infections ,Myocardial Infarction ,Risk Factors ,Plaque ,Atherosclerotic ,Tobacco Products - Abstract
OBJECTIVES: People with HIV have a higher risk of myocardial infarction (MI) than the general population, with a greater proportion of type 2 MI (T2MI) due to oxygen demand-supply mismatch compared with type 1 (T1MI) resulting from atherothrombotic plaque disruption. People living with HIV report a greater prevalence of cigarette and alcohol use than do the general population. Alcohol use and smoking as risk factors for MI by type are not well studied among people living with HIV. We examined longitudinal associations between smoking and alcohol use patterns and MI by type among people living with HIV. DESIGN AND METHODS: Using longitudinal data from the Centers for AIDS Research Network of Integrated Clinical Systems cohort, we conducted time-updated Cox proportional hazards models to determine the impact of smoking and alcohol consumption on adjudicated T1MI and T2MI. RESULTS: Among 13 506 people living with HIV, with a median 4 years of follow-up, we observed 177 T1MI and 141 T2MI. Current smoking was associated with a 60% increase in risk of both T1MI and T2MI. In addition, every cigarette smoked per day was associated with a 4% increase in risk of T1MI, with a suggestive, but not significant, 2% increase for T2MI. Cigarette use had a greater impact on T1MI for men than for women and on T2MI for women than for men. Increasing alcohol use was associated with a lower risk of T1MI but not T2MI. Frequency of heavy episodic alcohol use was not associated with MI. CONCLUSIONS: Our findings reinforce the prioritization of smoking reduction, even without cessation, and cessation among people living with HIV for MI prevention and highlight the different impacts on MI type by gender.
- Published
- 2023
10. Chronic obstructive pulmonary disease and the risk for myocardial infarction by type in people with HIV.
- Author
-
Crothers, Kristina, Nance, Robin, Whitney, Bridget, Harding, Barbara, Heckbert, Susan, Mathews, William, Bamford, Laura, Cachay, Edward, Eron, Joseph, Napravnik, Sonia, Moore, Richard, Keruly, Jeanne, Willig, Amanda, Burkholder, Greer, Feinstein, Matthew, Saag, Michael, Kitahata, Mari, Crane, Heidi, Delaney, Joseph, and Budoff, Matthew
- Subjects
Humans ,HIV Infections ,Myocardial Infarction ,Pulmonary Disease ,Chronic Obstructive ,Smoking - Abstract
OBJECTIVES: The relationship between chronic obstructive pulmonary disease (COPD) and cardiovascular disease in people with HIV (PWH) is incompletely understood. We determined whether COPD is associated with risk of myocardial infarction (MI) among PWH, and if this differs for type 1 (T1MI) and type 2 (T2MI). DESIGN: We utilized data from five sites in the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) cohort, a multisite observational study. METHODS: Our primary outcome was an adjudicated MI, classified as T1MI or T2MI. We defined COPD based on a validated algorithm requiring COPD diagnosis codes and at least 90-day continuous supply of inhalers. We conducted time-to-event analyses to first MI and used multivariable Cox proportional hazards models to measure associations between COPD and MI. RESULTS: Among 12 046 PWH, 945 had COPD. Overall, 309 PWH had an MI: 58% had T1MI ( N = 178) and 42% T2MI ( N = 131). In adjusted models, COPD was associated with a significantly increased risk of all MI [adjusted hazard ratio (aHR) 2.68 (95% confidence interval (CI) 1.99-3.60)] even after including self-reported smoking [aHR 2.40 (95% CI 1.76-3.26)]. COPD was also associated with significantly increased risk of T1MI and T2MI individually, and with sepsis and non-sepsis causes of T2MI. Associations were generally minimally changed adjusting for substance use. CONCLUSION: COPD is associated with a substantially increased risk for MI, including both T1MI and T2MI, among PWH. Given the association with both T1MI and T2MI, diverse mechanistic pathways are involved. Future strategies to decrease risk of T1MI and T2MI in PWH who have COPD are needed.
- Published
- 2023
11. HIV post-treatment controllers have distinct immunological and virological features
- Author
-
Etemad, Behzad, Sun, Xiaoming, Li, Yijia, Melberg, Meghan, Moisi, Daniela, Gottlieb, Rachel, Ahmed, Hayat, Aga, Evgenia, Bosch, Ronald J, Acosta, Edward P, Yuki, Yuko, Martin, Maureen P, Carrington, Mary, Gandhi, Rajesh T, Jacobson, Jeffrey M, Volberding, Paul, Connick, Elizabeth, Mitsuyasu, Ronald, Frank, Ian, Saag, Michael, Eron, Joseph J, Skiest, Daniel, Margolis, David M, Havlir, Diane, Schooley, Robert T, Lederman, Michael M, Yu, Xu G, and Li, Jonathan Z
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Immunology ,HIV/AIDS ,Infectious Diseases ,Infection ,Good Health and Well Being ,Humans ,CD8-Positive T-Lymphocytes ,Killer Cells ,Natural ,Lymphocyte Activation ,RNA ,HIV Infections ,Viremia ,HIV ,analytical treatment interruption ,post-treatment controller ,reservoir ,T cell - Abstract
HIV post-treatment controllers (PTCs) are rare individuals who maintain low levels of viremia after stopping antiretroviral therapy (ART). Understanding the mechanisms of HIV post-treatment control will inform development of strategies aiming at achieving HIV functional cure. In this study, we evaluated 22 PTCs from 8 AIDS Clinical Trials Group (ACTG) analytical treatment interruption (ATI) studies who maintained viral loads ≤400 copies/mL for ≥24 wk. There were no significant differences in demographics or frequency of protective and susceptible human leukocyte antigen (HLA) alleles between PTCs and post-treatment noncontrollers (NCs, n = 37). Unlike NCs, PTCs demonstrated a stable HIV reservoir measured by cell-associated RNA (CA-RNA) and intact proviral DNA assay (IPDA) during analytical treatment interruption (ATI). Immunologically, PTCs demonstrated significantly lower CD4+ and CD8+ T cell activation, lower CD4+ T cell exhaustion, and more robust Gag-specific CD4+ T cell responses and natural killer (NK) cell responses. Sparse partial least squares discriminant analysis (sPLS-DA) identified a set of features enriched in PTCs, including a higher CD4+ T cell% and CD4+/CD8+ ratio, more functional NK cells, and a lower CD4+ T cell exhaustion level. These results provide insights into the key viral reservoir features and immunological profiles for HIV PTCs and have implications for future studies evaluating interventions to achieve an HIV functional cure.
- Published
- 2023
12. Assessing the associations between known genetic variants and substance use in people with HIV in the United States.
- Author
-
Haas, Cameron, Jordahl, Kristina, Nance, Robin, Whitney, Bridget, Wang, Lu, Delaney, Joseph, Ruderman, Stephanie, Jia, Tongqiu, Saag, Michael, Lee, Sulggi, Napravnik, Sonia, Jacobson, Jeffrey, Chander, Geetanjali, McCall, Elizabeth, Moore, Richard, Mayer, Kenneth, Mukherjee, Shubhabrata, Lee, Won, Crane, Paul, Crane, Heidi, Peter, Inga, Lindström, Sara, and Mathews, Christopher
- Subjects
Humans ,United States ,Genome-Wide Association Study ,Smoking ,Alcohol Drinking ,Substance-Related Disorders ,Cannabis ,Ethanol ,HIV Infections - Abstract
BACKGROUND: The prevalence of substance use in people with HIV (PWH) in the United States is higher than in the general population and is an important driver of HIV-related outcomes. We sought to assess if previously identified genetic associations that contribute to substance use are also observed in a population of PWH. METHODS: We performed genome-wide association studies (GWAS) of alcohol, smoking, and cannabis use phenotypes in a multi-ancestry population of 7,542 PWH from the Center for AIDS Research Network of Integrated Clinical Systems (CNICS). We conducted multi-ancestry GWAS for individuals of African (n = 3,748), Admixed American (n = 1,334), and European (n = 2,460) ancestry. Phenotype data were self-reported and collected using patient reported outcomes (PROs) and three questions from AUDIT-C, an alcohol screening tool. We analyzed nine phenotypes: 1) frequency of alcohol consumption, 2) typical number of drinks on a day when drinking alcohol, 3) frequency of five or more alcoholic drinks in a 30-day period, 4) smoking initiation, 5) smoking cessation, 6) cigarettes per day, 7) cannabis use initiation, 8) cannabis use cessation, 9) frequency of cannabis use during the previous 30 days. For each phenotype we considered a) variants previously identified as associated with a substance use trait and b) novel associations. RESULTS: We observed evidence for effects of previously reported single nucleotide polymorphisms (SNPs) related to alcohol (rs1229984, p = 0.001), tobacco (rs11783093, p = 2.22E-4), and cannabis use (rs2875907, p = 0.005). We also report two novel loci (19p13.2, p = 1.3E-8; and 20p11.21, p = 2.1E-8) associated with cannabis use cessation. CONCLUSIONS: Our analyses contribute to understanding the genetic bases of substance use in a population with relatively higher rates of use compared to the general population.
- Published
- 2023
13. Differences in internalized HIV stigma across subpopulations of people with HIV in care across the United States
- Author
-
Drumright, Lydia N., Johnson, Mallory O., Mayer, Kenneth H., Christopoulos, Katerina, Cachay, Edward, Crawford, Timothy N., Whitney, Bridget M., Dai, Mindy, Ruderman, Stephanie A., Mixson, L. Sarah, Keruly, Jeanne C., Chander, Geetanjali, Saag, Michael S., Kitahata, Mari M., Moore, Richard D., Willig, Amanda L., Eron, Joseph J., Napravnik, Sonia, Nance, Robin M., Hahn, Andrew, Ma, Jimmy, Bamford, Laura, Fredericksen, Rob J., Delaney, Joseph A.C., and Crane, Heidi M.
- Published
- 2024
- Full Text
- View/download PDF
14. The effect of cystic echinococcosis (hydatid disease) on carcase weight in cattle in eastern Australia
- Author
-
Victoria J. Brookes, Tamsin S. Barnes, David J. Jenkins, Matthew R. Van der Saag, Robert Dempster, and Cara S. Wilson
- Subjects
Medicine ,Science - Abstract
Abstract Cystic echinococcosis is caused by the zoonotic tapeworm Echinococcus granulosus. There has been ongoing controversy over whether it causes weight loss in cattle. Recently implemented recording of comorbidities at processors has provided opportunity to investigate this effect. Using prevalence-based observational data from 1,648,049 adult cattle processed in seven states and territories in Australia (2019–2022), we explored associations between carcase weight, hydatid cysts, comorbidities, sex, age, and region. Linear mixed-effect regression models estimated the effect of cystic echinococcosis on carcase weight, guided by directed acyclic graphs to reduce bias. The highest, previously unreported, prevalence was in the southeast Queensland region. The estimated effect of cystic echinococcosis cysts on carcase weight ranged from a gain of 0.32 kg/carcase (standard error [se] 0.58 kg; two-tooth 2022) to a loss of −5.45 kg/carcase (se 0.63 kg; six-tooth 2019) with most point estimates (11/16) between 0 and −2.5 kg across all cattle grouped by year and dentition. This effect size would be practically undetectable in live cattle which is an important finding; cattle producers are unlikely to observe increased productivity through weight gain from cystic echinococcosis prevention in cattle, and awareness to strengthen prevention in domestic dogs around cattle properties to reduce human risk remains a public health focus.
- Published
- 2024
- Full Text
- View/download PDF
15. Associations between drug and alcohol use, smoking, and frailty among people with HIV across the United States in the current era of antiretroviral treatment.
- Author
-
Greene, Meredith, Hahn, Andrew, Eron, Joseph, Napravnik, Sonia, Mathews, William, Chander, Geetanjali, McCaul, Mary, Cachay, Edward, Mayer, Kenneth, Landay, Alan, Austad, Steven, Ma, Jimmy, Kritchevsky, Stephen, Pandya, Chintan, Achenbach, Chad, Cartujano-Barrera, Francisco, Kitahata, Mari, Delaney, Joseph, Kamen, Charles, Crane, Heidi, Ruderman, Stephanie, Whitney, Bridget, Nance, Robin, Drumright, Lydia, Webel, Allison, Willig, Amanda, Saag, Michael, and Christopoulos, Katerina
- Subjects
Alcohol use ,Cigarette smoking ,Frailty ,HIV ,Methamphetamine use ,Substance use ,Humans ,Aged ,United States ,Frailty ,Frail Elderly ,Geriatric Assessment ,Analgesics ,Opioid ,HIV Infections ,Methamphetamine ,Cocaine ,Smoking - Abstract
OBJECTIVE: To examine associations between frailty and drug, alcohol, and tobacco use among a large diverse cohort of people with HIV (PWH) in clinical care in the current era. METHODS: PWH at 7 sites across the United States completed clinical assessments of patient-reported measures and outcomes between 2016 and 2019 as part of routine care including drug and alcohol use, smoking, and other domains. Frailty was assessed using 4 of the 5 components of the Fried frailty phenotype and PWH were categorized as not frail, pre-frail, or frail. Associations of substance use with frailty were assessed with multivariate Poisson regression. RESULTS: Among 9336 PWH, 43% were not frail, 44% were prefrail, and 13% were frail. Frailty was more prevalent among women, older PWH, and those reporting current use of drugs or cigarettes. Current methamphetamine use (1.26: 95% CI 1.07-1.48), current (1.65: 95% CI 1.39-1.97) and former (1.21:95% CI 1.06-1.36) illicit opioid use, and former cocaine/crack use (1.17: 95% CI 1.01-1.35) were associated with greater risk of being frail in adjusted analyses. Current smoking was associated with a 61% higher risk of being frail vs. not frail (1.61: 95% CI 1.41-1.85) in adjusted analyses. CONCLUSIONS: We found a high prevalence of prefrailty and frailty among a nationally distributed cohort of PWH in care. This study identified distinct risk factors that may be associated with frailty among PWH, many of which, such as cigarette smoking and drug use, are potentially modifiable.
- Published
- 2022
16. Tobacco smoking and binge alcohol use are associated with incident venous thromboembolism in an HIV cohort.
- Author
-
Luu, Brandon, Ruderman, Stephanie, Nance, Robin, Delaney, Joseph AC, Ma, Jimmy, Hahn, Andrew, Heckbert, Susan R, Budoff, Matthew J, Crothers, Kristina, Mathews, William C, Christopolous, Katerina, Hunt, Peter W, Eron, Joseph, Moore, Richard, Keruly, Jeanne, Lober, William B, Burkholder, Greer A, Willig, Amanda, Chander, Geetanjali, McCaul, Mary E, Cropsey, Karen, O'Cleirigh, Conall, Peter, Inga, Feinstein, Matthew, Tsui, Judith I, Lindstroem, Sara, Saag, Michael, Kitahata, Mari M, Crane, Heidi M, Drumright, Lydia N, and Whitney, Bridget M
- Subjects
Humans ,HIV Infections ,Ethanol ,Proportional Hazards Models ,Risk Factors ,Prospective Studies ,Venous Thromboembolism ,Binge Drinking ,Tobacco Smoking ,HIV ,binge drinking ,smoking ,substance use ,venous thromboembolism ,Substance Misuse ,Alcoholism ,Alcohol Use and Health ,Tobacco Smoke and Health ,Prevention ,Clinical Research ,HIV/AIDS ,Tobacco ,Prevention of disease and conditions ,and promotion of well-being ,3.1 Primary prevention interventions to modify behaviours or promote wellbeing ,Cancer ,Stroke ,Cardiovascular ,Respiratory ,Good Health and Well Being ,Clinical Sciences ,Virology - Abstract
BackgroundPeople with HIV (PWH) are at increased risk of cardiovascular comorbidities and substance use is a potential predisposing factor. We evaluated associations of tobacco smoking and alcohol use with venous thromboembolism (VTE) in PWH.MethodsWe assessed incident, centrally adjudicated VTE among 12 957 PWH within the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) cohort between January 2009 and December 2018. Using separate Cox proportional hazards models, we evaluated associations of time-updated alcohol and cigarette use with VTE, adjusting for demographic and clinical characteristics. Smoking was evaluated as pack-years and never, former, or current use with current cigarettes per day. Alcohol use was parameterized using categorical and continuous alcohol use score, frequency of use, and binge frequency.ResultsDuring a median of 3.6 years of follow-up, 213 PWH developed a VTE. One-third of PWH reported binge drinking and 40% reported currently smoking. In adjusted analyses, risk of VTE was increased among both current (HR: 1.44, 95% CI: 1.02-2.03) and former (HR: 1.44, 95% CI: 0.99-2.07) smokers compared to PWH who never smoked. Additionally, total pack-years among ever-smokers (HR: 1.10 per 5 pack-years; 95% CI: 1.03-1.18) was associated with incident VTE in a dose-dependent manner. Frequency of binge drinking was associated with incident VTE (HR: 1.30 per 7 days/month, 95% CI: 1.11-1.52); however, alcohol use frequency was not. Severity of alcohol use was not significantly associated with VTE.ConclusionsCurrent smoking and pack-year smoking history were dose-dependently associated with incident VTE among PWH in CNICS. Binge drinking was also associated with VTE. Interventions for smoking and binge drinking may decrease VTE risk among PWH.
- Published
- 2022
17. Current Antiretroviral Treatment Among People With Human Immunodeficiency Virus in the United States: Findings from the Centers for AIDS Research Network of Integrated Clinic Systems Cohort
- Author
-
Ma, Jimmy, Nance, Robin M, Delaney, Joseph AC, Whitney, Bridget M, Bamford, Laura, Gravett, Ronnie M, Moore, Richard D, Napravnik, Sonia, Mayer, Kenneth H, Jacobson, Jeffrey M, Christopoulos, Katerina, Burkholder, Greer A, Keruly, Jeanne, Eron, Joseph J, Martin, Jeffrey, Cachay, Edward R, Saag, Michael S, Crane, Heidi M, and Kitahata, Mari M
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Infectious Diseases ,Sexually Transmitted Infections ,HIV/AIDS ,Infection ,Good Health and Well Being ,Acquired Immunodeficiency Syndrome ,Alanine ,Anti-HIV Agents ,Anti-Retroviral Agents ,Emtricitabine ,HIV ,HIV Infections ,Heterocyclic Compounds ,3-Ring ,Humans ,Tenofovir ,United States ,ART utilization ,ART treatment trends ,ART guidelines ,integrase inhibitor ,tenofovir alafenamide ,Biological Sciences ,Medical and Health Sciences ,Microbiology ,Clinical sciences - Abstract
Among 14 049 people with human immunodeficiency virus in care in 2019-2020, 96% were treated with antiretroviral therapy (ART). Current antiretroviral treatment patterns highlight high uptake of guideline-recommended ART regimens including second-generation integrase strand transfer inhibitors (dolutegravir and bictegravir) and tenofovir alafenamide, especially in antiretroviral-naive individuals initiating ART.
- Published
- 2022
18. Discrimination and Calibration of the Veterans Aging Cohort Study Index 2.0 for Predicting Mortality Among People With Human Immunodeficiency Virus in North America
- Author
-
McGinnis, Kathleen A, Justice, Amy C, Moore, Richard D, Silverberg, Michael J, Althoff, Keri N, Karris, Maile, Lima, Viviane D, Crane, Heidi M, Horberg, Michael A, Klein, Marina B, Gange, Stephen J, Gebo, Kelly A, Mayor, Angel, Tate, Janet P, Benson, Constance A, Bosch, Ronald J, Kirk, Gregory D, Marconi, Vincent, Colasanti, Jonathan, Mayer, Kenneth H, Grasso, Chris, Hogg, Robert S, Montaner, Julio SG, Sereda, Paul, Salters, Kate, Buchacz, Kate, Li, Jun, Jacobson, Jeffrey M, Thorne, Jennifer E, Brown, Todd, Tien, Phyllis, D’Souza, Gypsyamber, Smith, Graham, Loutfy, Mona, Gupta, Meenakshi, Rabkin, Charles, Kroch, Abigail, Burchell, Ann, Betts, Adrian, Lindsay, Joanne, Nijhawan, Ank, Mayor, Angel M, Gill, M John, Martin, Jeffrey N, Brooks, John T, Saag, Michael S, Mugavero, Michael J, Willig, James, Bamford, Laura, Eron, Joseph J, Napravnik, Sonia, Kitahata, Mari M, Sterling, Timothy R, Haas, David, Rebeiro, Peter, Turner, Megan, Lee, Jennifer S, McKaig, Rosemary G, Freeman, Aimee M, Van Rompaey, Stephen E, Morton, Liz, McReynolds, Justin, Lober, William B, Hogan, Brenna, You, Bin, Humes, Elizabeth, Gerace, Lucas, Stewart, Cameron, and Coburn, Sally
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Sexually Transmitted Infections ,Aging ,Infectious Diseases ,Women's Health ,HIV/AIDS ,Aetiology ,2.4 Surveillance and distribution ,Infection ,Good Health and Well Being ,Calibration ,Cohort Studies ,Female ,HIV ,HIV Infections ,Humans ,Male ,Middle Aged ,North America ,Veterans ,VACS Index 2.0 ,calibration ,mortality ,North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD)a of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) and Veterans Aging Cohort Study ,Biological Sciences ,Medical and Health Sciences ,Microbiology ,Clinical sciences - Abstract
BackgroundThe updated Veterans Aging Cohort Study (VACS) Index 2.0 combines general and human immunodeficiency virus (HIV)-specific biomarkers to generate a continuous score that accurately discriminates risk of mortality in diverse cohorts of persons with HIV (PWH), but a score alone is difficult to interpret. Using data from the North American AIDS Cohort Collaboration (NA-ACCORD), we translate VACS Index 2.0 scores into validated probability estimates of mortality.MethodsBecause complete mortality ascertainment is essential for accurate calibration, we restricted analyses to cohorts with mortality from the National Death Index or equivalent sources. VACS Index 2.0 components were ascertained from October 1999 to April 2018. Mortality was observed up to March 2019. Calibration curves compared predicted (estimated by fitting a gamma model to the score) to observed mortality overall and within subgroups: cohort (VACS/NA-ACCORD subset), sex, age 500 copies/mL, CD4 count
- Published
- 2022
19. Factors Associated With Severity of COVID-19 Disease in a Multicenter Cohort of People With HIV in the United States, March–December 2020
- Author
-
Shapiro, Adrienne E, Ignacio, Rachel A Bender, Whitney, Bridget M, Delaney, Joseph A, Nance, Robin M, Bamford, Laura, Wooten, Darcy, Keruly, Jeanne C, Burkholder, Greer, Napravnik, Sonia, Mayer, Kenneth H, Webel, Allison R, Kim, H Nina, Van Rompaey, Stephen E, Christopoulos, Katerina, Jacobson, Jeffrey, Karris, Maile, Smith, Davey, Johnson, Mallory O, Willig, Amanda, Eron, Joseph J, Hunt, Peter, Moore, Richard D, Saag, Michael S, Mathews, W Christopher, Crane, Heidi M, Cachay, Edward R, Kitahata, Mari M, and Systems, for the CFAR Network of Integrated Clinical
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Health Sciences ,Lung ,Prevention ,Coronaviruses ,Sexually Transmitted Infections ,Infectious Diseases ,Emerging Infectious Diseases ,Clinical Research ,HIV/AIDS ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Good Health and Well Being ,CD4 Lymphocyte Count ,COVID-19 ,COVID-19 Vaccines ,HIV Infections ,Humans ,Renal Insufficiency ,Chronic ,United States ,HIV ,CD4 count ,structural determinants of health ,immunosuppression ,CFAR Network of Integrated Clinical Systems ,Public Health and Health Services ,Virology ,Clinical sciences ,Epidemiology ,Public health - Abstract
BackgroundUnderstanding the spectrum of COVID-19 in people with HIV (PWH) is critical to provide clinical guidance and risk reduction strategies.SettingCenters for AIDS Research Network of Integrated Clinic System, a US multisite clinical cohort of PWH in care.MethodsWe identified COVID-19 cases and severity (hospitalization, intensive care, and death) in a large, diverse HIV cohort during March 1, 2020-December 31, 2020. We determined predictors and relative risks of hospitalization among PWH with COVID-19, adjusted for disease risk scores.ResultsOf 16,056 PWH in care, 649 were diagnosed with COVID-19 between March and December 2020. Case fatality was 2%; 106 (16.3%) were hospitalized, and 12 died. PWH with current CD4 count
- Published
- 2022
20. Racial and ethnic disparities in coronavirus disease 2019 disease incidence independent of comorbidities, among people with HIV in the United States
- Author
-
Ignacio, Rachel A Bender, Shapiro, Adrienne E, Nance, Robin M, Whitney, Bridget M, Delaney, Joseph AC, Bamford, Laura, Wooten, Darcy, Karris, Maile Y, Mathews, William C, Kim, Hyang Nina, Keruly, Jeanne, Burkholder, Greer, Napravnik, Sonia, Mayer, Kenneth H, Jacobson, Jeffrey, Saag, Michael, Moore, Richard D, Eron, Joseph J, Willig, Amanda L, Christopoulos, Katerina A, Martin, Jeffrey, Hunt, Peter W, Crane, Heidi M, Kitahata, Mari M, and Cachay, Edward R
- Subjects
Biomedical and Clinical Sciences ,Public Health ,Health Sciences ,Infectious Diseases ,Emerging Infectious Diseases ,Clinical Research ,Sexually Transmitted Infections ,Substance Misuse ,Prevention ,Coronaviruses Disparities and At-Risk Populations ,Health Disparities ,Coronaviruses ,Social Determinants of Health ,Minority Health ,HIV/AIDS ,Good Health and Well Being ,Adult ,COVID-19 ,COVID-19 Testing ,Ethnicity ,Female ,HIV Infections ,Humans ,Incidence ,Middle Aged ,United States ,coronavirus disease 2019 acquisition ,HIV ,immune exhaustion ,racial disparities ,Centers for AIDS Research Network of Integrated Clinical Systems ,Biological Sciences ,Medical and Health Sciences ,Psychology and Cognitive Sciences ,Virology ,Biomedical and clinical sciences ,Health sciences - Abstract
ObjectivesTo define the incidence of clinically detected coronavirus disease 2019 (COVID-19) in people with HIV (PWH) in the United States and evaluate how racial and ethnic disparities, comorbidities, and HIV-related factors contribute to risk of COVID-19.DesignObservational study within the CFAR Network of Integrated Clinical Systems cohort in seven cities during 2020.MethodsWe calculated cumulative incidence rates of COVID-19 diagnosis among PWH in routine care by key characteristics including race/ethnicity, current and lowest CD4+ cell count, and geographic area. We evaluated risk factors for COVID-19 among PWH using relative risk regression models adjusted with disease risk scores.ResultsAmong 16 056 PWH in care, of whom 44.5% were black, 12.5% were Hispanic, with a median age of 52 years (IQR 40-59), 18% had a current CD4+ cell count less than 350 cells/μl, including 7% less than 200; 95.5% were on antiretroviral therapy (ART), and 85.6% were virologically suppressed. Overall in 2020, 649 PWH were diagnosed with COVID-19 for a rate of 4.94 cases per 100 person-years. The cumulative incidence of COVID-19 was 2.4-fold and 1.7-fold higher in Hispanic and black PWH respectively, than non-Hispanic white PWH. In adjusted analyses, factors associated with COVID-19 included female sex, Hispanic or black identity, lowest historical CD4+ cell count less than 350 cells/μl (proxy for CD4+ nadir), current low CD4+ : CD8+ ratio, diabetes, and obesity.ConclusionOur results suggest that the presence of structural racial inequities above and beyond medical comorbidities increased the risk of COVID-19 among PWH. PWH with immune exhaustion as evidenced by lowest historical CD4+ cell count or current low CD4+ : CD8+ ratio had greater risk of COVID-19.
- Published
- 2022
21. Monosodium urate crystal depletion and bone erosion remodeling during pegloticase treatment in patients with uncontrolled gout: Exploratory dual-energy computed tomography findings from MIRROR RCT
- Author
-
Dalbeth, Nicola, Botson, John, Saag, Kenneth, Kumar, Ada, Padnick-Silver, Lissa, LaMoreaux, Brian, and Becce, Fabio
- Published
- 2024
- Full Text
- View/download PDF
22. HIV Symptom Clusters are Similar Using the Dimensions of Symptom Occurrence and Distress
- Author
-
Wilson, Natalie L, Hoffman, Thomas J, Heath, Sonya L, Saag, Michael S, and Miaskowski, Christine
- Subjects
Health Services and Systems ,Nursing ,Health Sciences ,Infectious Diseases ,HIV/AIDS ,Sexually Transmitted Infections ,Pain Research ,Antineoplastic Agents ,Factor Analysis ,Statistical ,HIV Infections ,Humans ,Pain ,Syndrome ,Symptoms ,symptom clusters ,exploratory factor analysis ,HIV ,occurrence ,distress ,HIV Symptom Index ,Medical and Health Sciences ,Anesthesiology ,Biomedical and clinical sciences ,Health sciences - Abstract
ContextPeople living with HIV infection (PLWH) in the United States continue to experience a high symptom burden despite improvements in antiretroviral therapy.ObjectivesThe purpose of this study was to determine if the number and types of symptom clusters differed based on whether symptom occurrence rates or distress ratings were used to create the clusters.MethodsData from 2,000 patients with complete symptom occurrence rates and distress scores on the 20-item HIV Symptom Index from their first ambulatory clinic visit at one of six national HIV centers of excellence in the Center for AIDS Research Network of Integrated Clinical Systems were used in these analyses. Exploratory factor analysis was used to create the symptom clusters.ResultsThe same four symptom clusters (i.e., gastrointestinal, psychological, pain, body image) were identified using occurrence rates and distress ratings. For both dimensions of the symptom experience, the psychological, pain, and body image clusters each had the same symptoms. For the gastrointestinal cluster, four symptoms loaded on the occurrence dimension and six symptoms loaded on the distress dimension.ConclusionThe number and types of symptom clusters were relatively similar across the occurrence and distress dimensions of the symptom experience. Symptom clusters in PLWH may provide insights into the development of targeted interventions for multiple co-occurring symptoms.
- Published
- 2022
23. Risk factors for atrial fibrillation in a multicenter United States clinical cohort of people with HIV infection
- Author
-
Nance, Robin M, Delaney, Joseph AC, Floyd, James S, Saag, Michael S, Moore, Richard D, Keruly, Jeanne C, Kitahata, Mari M, Whitney, Bridget M, Mathews, W Chris, Cachay, Edward R, Burkholder, Greer, Willig, Amanda L, Eron, Joseph J, Napravnik, Sonia, Crane, Heidi M, and Heckbert, Susan R
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Cardiovascular ,Clinical Research ,Prevention ,Heart Disease ,Clinical Trials and Supportive Activities ,Infectious Diseases ,Patient Safety ,HIV/AIDS ,Aetiology ,2.1 Biological and endogenous factors ,Infection ,Anti-Retroviral Agents ,Atrial Fibrillation ,Cohort Studies ,HIV Infections ,Humans ,Risk Factors ,United States ,Biological Sciences ,Medical and Health Sciences ,Psychology and Cognitive Sciences ,Virology ,Biomedical and clinical sciences ,Health sciences - Abstract
To assess atrial fibrillation risk factors in people with HIV, we identified incident atrial fibrillation in a large clinical cohort of people receiving care. Compared with 970 controls without atrial fibrillation, the 97 with adjudicated incident atrial fibrillation were older, less likely Hispanic, and had more coronary disease, heart failure, and chronic obstructive pulmonary disease. In multivariable analysis, nonuse of antiretroviral therapy and prescription of antiretroviral regimens with multiple core agents were associated with increased atrial fibrillation risk.
- Published
- 2022
24. Brief Report: Insomnia and Risk of Myocardial Infarction Among People With HIV
- Author
-
Luu, Brandon R, Nance, Robin M, Delaney, Joseph AC, Ruderman, Stephanie A, Heckbert, Susan R, Budoff, Matthew J, Mathews, William C, Moore, Richard D, Feinstein, Matthew J, Burkholder, Greer A, Mugavero, Michael J, Eron, Joseph J, Saag, Michael S, Kitahata, Mari M, Crane, Heidi M, and Whitney, Bridget M
- Subjects
Clinical Research ,Heart Disease ,Prevention ,HIV/AIDS ,Heart Disease - Coronary Heart Disease ,Infectious Diseases ,Cardiovascular ,Good Health and Well Being ,Acquired Immunodeficiency Syndrome ,HIV Infections ,Humans ,Longitudinal Studies ,Myocardial Infarction ,Sleep Initiation and Maintenance Disorders ,HIV ,insomnia ,myocardial infarction ,type 1 myocardial infarction ,type 2 myocardial infarction ,Clinical Sciences ,Public Health and Health Services ,Virology - Abstract
BackgroundInsomnia is common among people with HIV (PWH) and may be associated with increased risk of myocardial infarction (MI). This study examines the association between insomnia and MI by MI type among PWH.SettingLongitudinal cohort study of PWH at 5 Centers for AIDS Research Network of Integrated Clinical Systems sites.MethodsClinical data and patient-reported measures and outcomes from PWH in care between 2005 and 2018 were used in this study. Insomnia, measured at baseline, was defined as having difficulty falling or staying asleep with bothersome symptoms. The Centers for AIDS Research Network of Integrated Clinical Systems centrally adjudicates MIs using expert reviewers, with distinction between type 1 MI (T1MI) and type 2 MI (T2MI). Associations between insomnia and first incident MI by MI type were measured using separate Cox proportional hazard models adjusted for age, sex, race/ethnicity, traditional cardiovascular disease risk factors (hypertension, dyslipidemia, poor kidney function, diabetes, and smoking), HIV markers (antiretroviral therapy, viral suppression, and CD4 cell count), and stimulant use (cocaine/crack and methamphetamine).ResultsAmong 12,448 PWH, 48% reported insomnia. Over a median of 4.4 years of follow-up, 158 T1MIs and 109 T2MIs were identified; approximately half of T2MIs were attributed to sepsis or stimulant use. After adjustment for potential confounders, we found no association between insomnia and T1MI (hazard ratio = 1.05, 95% confidence interval: 0.76 to 1.45) and a 65% increased risk of T2MI among PWH reporting insomnia compared with PWH without insomnia (hazard ratio = 1.65, 95% confidence interval: 1.11 to 2.45).ConclusionsPWH reporting insomnia are at an increased risk of T2MI, but not T1MI, compared with PWH without insomnia, highlighting the importance of distinguishing MI types among PWH.
- Published
- 2022
25. Anal cancer incidence in men with HIV who have sex with men: are black men at higher risk?
- Author
-
McNeil, Candice J, Lee, Jennifer S, Cole, Stephen R, Patel, Shivani A, Martin, Jeffrey, Mathews, William C, Moore, Richard D, Mayer, Kenneth H, Eron, Joseph J, Saag, Michael S, Kitahata, Mari M, and Achenbach, Chad J
- Subjects
Biomedical and Clinical Sciences ,Public Health ,Health Sciences ,Clinical Sciences ,Prevention ,Cancer ,Behavioral and Social Science ,Minority Health ,Infectious Diseases ,Sexually Transmitted Infections ,HIV/AIDS ,Digestive Diseases ,Health Disparities ,Hepatitis ,Liver Disease ,Sexual and Gender Minorities (SGM/LGBT*) ,Clinical Research ,Hepatitis - B ,Aetiology ,2.2 Factors relating to the physical environment ,Infection ,Good Health and Well Being ,Anus Neoplasms ,Cohort Studies ,Coinfection ,HIV Infections ,Homosexuality ,Male ,Humans ,Incidence ,Male ,Risk Factors ,Sexual and Gender Minorities ,AIDS ,anal cancer ,HIV ,men who have sex with men ,racial disparities ,on behalf of the Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems ,Biological Sciences ,Medical and Health Sciences ,Psychology and Cognitive Sciences ,Virology ,Biomedical and clinical sciences ,Health sciences - Abstract
ObjectiveTo assess differences in anal cancer incidence between racial/ethnic groups among a clinical cohort of men with HIV who have sex with men.DesignClinical cohort study.MethodsWe studied men who have sex with men (MSM) in the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) who initiated antiretroviral therapy (ART) under HIV care in CNICS. We compared anal cancer incidence between Black and non-Black men and calculated hazard ratios controlling for demographic characteristics (age, CNICS site, year of ART initiation), HIV disease indicators (nadir CD4+, peak HIV RNA), and co-infection/behavioral factors including hepatitis B virus (HBV), hepatitis C virus (HCV), tobacco smoking and alcohol abuse.ResultsWe studied 7473 MSM with HIV who contributed 41 810 person-years of follow-up after initiating ART between 1996 and 2014 in CNICS. Forty-one individuals had an incident diagnosis of anal cancer under observation. Crude rates of anal cancer were 204 versus 61 per 100 000 person-years among Black versus non-Black MSM. The weighted hazard ratio for anal cancer in Black MSM (adjusting for demographics, HIV disease factors, and co-infection/behavioral factors) was 2.37 (95% confidence interval: 1.17, 4.82) compared to non-Black MSM.ConclusionsIn this large multicenter cohort, Black MSM were at significantly increased risk for anal cancer compared to non-Black MSM. Further detailed studies evaluating factors impacting anal cancer incidence and outcomes in Black men with HIV are necessary. Inclusion of more diverse study cohorts may elucidate modifiable factors associated with increased anal cancer risk experienced by Black MSM.
- Published
- 2022
26. The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids
- Author
-
Saag, Kenneth G, McDermott, Michele T, Adachi, Jonathan, Lems, Willem, Lane, Nancy E, Geusens, Piet, Stad, Robert Kees, Chen, Li, Huang, Shuang, Dore, Robin, and Cohen, Stanley
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Osteoporosis ,Autoimmune Disease ,Clinical Trials and Supportive Activities ,Arthritis ,Clinical Research ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Musculoskeletal ,Arthritis ,Rheumatoid ,Bone Density ,Bone Density Conservation Agents ,Bone Remodeling ,Denosumab ,Glucocorticoids ,Humans ,Immunology ,Public Health and Health Services ,Arthritis & Rheumatology ,Clinical sciences - Abstract
ObjectiveTo evaluate changes in bone turnover and bone mineral density (BMD) in patients with rheumatoid arthritis (RA) receiving glucocorticoids, after discontinuation of denosumab for 12 months.MethodsWe conducted a randomized, double-blind, placebo-controlled, phase II study of RA patients. Patients received placebo, denosumab 60 mg, or denosumab 180 mg every 6 months for 12 months and were followed up for an additional 12 months after discontinuation, during which no bone loss prevention therapy was instituted. Changes from baseline in serum C-terminal telopeptide of type I collagen (CTX), serum procollagen type I N-terminal propeptide (PINP), and lumbar spine and total hip BMD were evaluated.ResultsIn this post hoc analysis of patients treated with glucocorticoids at study baseline (n = 82), levels of CTX and PINP decreased significantly from baseline in both denosumab groups. Following denosumab discontinuation, CTX returned to baseline and was not significantly different from the placebo group 6 and 12 months after discontinuation. Median percentage changes from baseline PINP in those treated with denosumab 60 mg were -0.16% and 15.3% at 6 and 12 months, respectively, after discontinuation (P = 0.062 and P = 0.017, versus placebo); corresponding changes with denosumab 180 mg were 9.0% and 75.8%, respectively (P = 0.018 and P = 0.002 versus placebo). Compared to placebo, lumbar spine and total hip BMD increased in patients receiving denosumab and returned to baseline 12 months after discontinuation. No osteoporotic fractures were reported during treatment or in the off-treatment period.ConclusionIn this analysis of short-term denosumab use in RA patients receiving glucocorticoids, denosumab discontinuation resulted in a gradual increase in bone turnover, which was associated with a return to baseline lumbar spine and total hip BMD.
- Published
- 2022
27. Osteoporosis Prevention and Treatment
- Author
-
Humphrey, Mary Beth, Zahedi, Bita, Warriner, Amy, Morgan, Sarah, Leder, Benjamin Z., Saag, Ken, Yu, Elaine W., and Stone, John H., editor
- Published
- 2023
- Full Text
- View/download PDF
28. Osteoporosis: Epidemiology and Assessment
- Author
-
Humphrey, Mary Beth, Zahedi, Bita, Warriner, Amy, Morgan, Sarah, Leder, Benjamin Z., Saag, Ken, Yu, Elaine W., and Stone, John H., editor
- Published
- 2023
- Full Text
- View/download PDF
29. A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase: 12‐Month Findings
- Author
-
John K. Botson, Kenneth Saag, Jeff Peterson, Katie Obermeyer, Yan Xin, Brian LaMoreaux, Lissa Padnick‐Silver, Supra Verma, Suneet Grewal, Amar Majjhoo, John R. P. Tesser, and Michael E. Weinblatt
- Subjects
Diseases of the musculoskeletal system ,RC925-935 - Abstract
Objective To assess 12‐month safety and efficacy of pegloticase + methotrexate (MTX) versus pegloticase + placebo (PBO) cotherapy in a PBO‐controlled, double‐blind trial (A randomized, double‐blind, placebo‐controlled, multicenter, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase [MIRROR RCT]). Methods Patients with uncontrolled gout (serum urate level [SU] ≥7 mg/dl, oral urate‐lowering therapy failure or intolerance, and presence of one or more gout symptoms [one or more tophi, two or more flares in 12 months, gouty arthropathy]) were randomized 2:1 to receive pegloticase (8‐mg infusion every 2 weeks) with blinded MTX (oral 15 mg/week) or PBO for 52 weeks. Efficacy end points included proportion of responders (SU level
- Published
- 2023
- Full Text
- View/download PDF
30. Risk of fracture in women with glucocorticoid requiring diseases is independent from glucocorticoid use: An analysis on a nation-wide database
- Author
-
Adami, Giovanni, Gatti, Davide, Rossini, Maurizio, Giollo, Alessandro, Gatti, Matteo, Bertoldo, Francesco, Bertoldo, Eugenia, Mudano, Amy S., Saag, Kenneth G., Viapiana, Ombretta, and Fassio, Angelo
- Published
- 2024
- Full Text
- View/download PDF
31. Drug and alcohol use among people living with HIV in care in the United States by geographic region
- Author
-
Crane, Heidi M, Nance, Robin M, Whitney, Bridget M, Ruderman, Stephanie, Tsui, Judith I, Chander, Geetanjali, McCaul, Mary E, Lau, Bryan, Mayer, Kenneth H, Batey, D Scott, Safren, Steven A, Moore, Richard D, Eron, Joseph J, Napravnik, Sonia, Mathews, W Chris, Fredericksen, Rob J, Hahn, Andrew W, Mugavero, Michael J, Lober, William B, Saag, Michael S, Kitahata, Mari M, and Delaney, Joseph AC
- Subjects
Clinical and Health Psychology ,Health Sciences ,Public Health ,Human Society ,Psychology ,Sociology ,Prevention ,Substance Misuse ,Methamphetamine ,Brain Disorders ,Alcoholism ,Alcohol Use and Health ,HIV/AIDS ,Drug Abuse (NIDA only) ,Good Health and Well Being ,Alcohol Drinking ,Analgesics ,Opioid ,Crack Cocaine ,HIV Infections ,Humans ,Practice Patterns ,Physicians' ,United States ,Drug use ,alcohol use ,marijuana ,methamphetamine ,HIV ,Public Health and Health Services ,Public health ,Clinical and health psychology - Abstract
Substance use in the U.S. varies by geographic region. Opioid prescribing practices and marijuana, heroin, and methamphetamine availability are evolving differently across regions. We examined self-reported substance use among people living with HIV (PLWH) in care at seven sites from 2017-2019 to understand current regional substance use patterns. We calculated the percentage and standardized percentage of PLWH reporting current drug use and at-risk and binge alcohol use by U.S. Census Bureau geographic region and examined associations in adjusted logistic regression analyses. Among 7,686 PLWH, marijuana use was the most prevalent drug (30%), followed by methamphetamine/crystal (8%), cocaine/crack (7%), and illicit opioids (3%). One-third reported binge alcohol use (32%). Differences in percent of current use by region were seen for marijuana (24-41%) and methamphetamine/crystal (2-15%), with more use in the West and Northeast, and binge alcohol use (26-40%). In adjusted analyses, PLWH in the Midwest were significantly less likely to use methamphetamine/crystal (aOR: 0.13;0.06-0.25) or illicit opioids (aOR:0.16;0.05-0.53), and PLWH in the Northeast were more likely to use cocaine/crack (aOR:1.59;1.16-2.17), compared to PLWH in the West. Understanding differences in substance use patterns in the current era, as policies continue to evolve, will enable more targeted interventions in clinical settings among PLWH.
- Published
- 2021
32. The impact of COVID-19 on mentoring early-career investigators
- Author
-
Johnson, Mallory O, Gandhi, Monica, Fuchs, Jonathan D, Sterling, Lauren, Sauceda, John A, Saag, Michael S, Riley, Elise D, and Sevelius, Jae M
- Subjects
Biomedical and Clinical Sciences ,Immunology ,Health Disparities ,Minority Health ,Behavioral and Social Science ,Women's Health ,HIV/AIDS ,Infectious Diseases ,Social Determinants of Health ,Emerging Infectious Diseases ,Coronaviruses ,Mental Health ,Clinical Research ,Sexually Transmitted Infections ,Coronaviruses Disparities and At-Risk Populations ,Basic Behavioral and Social Science ,Good Health and Well Being ,COVID-19 ,Cross-Sectional Studies ,Education ,Distance ,Female ,HIV Infections ,Humans ,Male ,Mentoring ,Pandemics ,Professional Competence ,Qualitative Research ,Research Personnel ,SARS-CoV-2 ,Stress ,Psychological ,United States ,AIDS ,career development ,HIV ,mentoring ,Clinical Sciences ,Arthritis & Rheumatology ,Biomedical and clinical sciences ,Clinical sciences - Abstract
AbstractThe COVID-19 pandemic disrupted almost all sectors of academic training and research, but the impact on human immunodeficiency virus (HIV) research mentoring has yet to be documented. We present the perspectives of diverse, experienced mentors in a range of HIV research disciplines on the impact of COVID-19 on mentoring the next generation of HIV researchers.In November to December, 2020, we used an online data collection platform to cross-sectionally query previously-trained HIV mentors on the challenges related to mentoring during the pandemic, surprising/positive aspects of mentoring in that context, and recommendations for other mentors. Data were coded and analyzed following a thematic analysis approach.Respondents (180 of 225 mentors invited [80% response]) reported challenges related to relationship building/maintenance, disruptions in mentees' training and research progress, and mentee and mentor distress, with particular concerns regarding mentees who are parents or from underrepresented minority backgrounds. Positive/surprising aspects included logistical ease of remote mentoring, the relationship-edifying result of the shared pandemic experience, mentee resilience and gratitude, and increased enjoyment of mentoring. Recommendations included practical tips, encouragement for patience and persistence, and prioritizing supporting mentees' and one's own mental well-being.Findings revealed gaps in HIV mentors' competencies, including the effective use of remote mentoring tools, how to work with mentees in times of distress, and the prioritization of mentor well-being. Mentors are in a unique position to identify and potentially address factors that may lead to mentees leaving their fields, especially parents and those from underrepresented backgrounds. We discuss implications beyond the COVID-19 pandemic.
- Published
- 2021
33. CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018
- Author
-
Lee, Jennifer S, Humes, Elizabeth A, Hogan, Brenna C, Buchacz, Kate, Eron, Joseph J, Gill, M John, Sterling, Timothy R, Rebeiro, Peter F, Lima, Viviane Dias, Mayor, Angel, Silverberg, Michael J, Horberg, Michael A, Moore, Richard D, Althoff, Keri N, Benson, Constance A, Bosch, Ronald J, Emory-Grady, Gregory D Kirk, Mayer, Kenneth H, Grasso, Chris, Hogg, Robert S, Harrigan, P Richard, Montaner, Julio SG, Yip, Benita, Zhu, Julia, Salters, Kate, Gabler, Karyn, Li, Jun, Gebo, Kelly A, Johns, Richard D Moore, Carey, John T, Rodriguez, Benigno, Thorne, Jennifer E, Brown, Todd, Tien, Phyllis, D’Souza, Gypsyamber, Crouzat, Frederic, Loutfy, Mona, Smith, Graham, Gupta, Meenakshi, Klein, Marina B, Rabkin, Charles, Kroch, Abigail, Burchell, Ann, Betts, Adrian, Lindsay, Joanne, Nijhawan, Ank, Hunter-Mellado, Robert F, Mayor, Angel M, Martin, Jeffrey N, Brooks, John T, Saag, Michael S, Mugavero, Michael J, Willig, James, Bamford, Laura, Karris, Maile, Napravnik, Sonia, Kitahata, Mari M, Crane, Heidi M, Haas, David, Rebeiro, Peter, Turner, Megan, Park, Lesley, Justice, Amy, Gange, Stephen J, McKaig, Rosemary G, Freeman, Aimee M, Van Rompaey, Stephen E, Morton, Liz, McReynolds, Justin, Lober, William B, Hogan, Brenna, You, Bin, Humes, Elizabeth, Gerace, Lucas, Stewart, Cameron, and Coburn, Sally
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Adult ,Anti-HIV Agents ,Antiretroviral Therapy ,Highly Active ,CD4 Lymphocyte Count ,HIV ,HIV Infections ,Humans ,Prescriptions ,United States ,North American AIDS Cohort Collaboration on Research and Design ,CD4 count ,antiretroviral therapy ,treat all ,universal treatment ,Biological Sciences ,Medical and Health Sciences ,Microbiology ,Clinical sciences - Abstract
From 2005 to 2018, among 32013 adults with human immunodeficiency virus entering care, median time to antiretroviral therapy (ART) prescription declined from 69 to 6 days, CD4 count at entry into care increased from 300 to 362 cells/μL, and CD4 count at ART prescription increased from 160 to 364 cells/μL.
- Published
- 2021
34. Weight loss associated with semaglutide treatment among people with HIV
- Author
-
Haidar, Lara, Crane, Heidi M., Nance, Robin M., Webel, Allison, Ruderman, Stephanie A., Whitney, Bridget M., Willig, Amanda L., Napravnik, Sonia, Mixson, L. Sarah, Leong, Christine, Lavu, Alekhya, Aboulatta, Laila, Dai, Mindy, Hahn, Andrew, Saag, Michael S., Bamford, Laura, Cachay, Edward, Kitahata, Mari M., Mayer, Kenneth H., Jacobson, Jeffrey, Moore, Richard D., Delaney, Joseph A.C., Drumright, Lydia N., and Eltonsy, Sherif
- Published
- 2024
- Full Text
- View/download PDF
35. Pain Relief Interventions in Australian Livestock Husbandry: A Review of Animal Welfare and Pain Duration
- Author
-
Lee Metcalf, Sabrina Lomax, Dominique Van der Saag, Sanjay Garg, and Peter J. White
- Subjects
pain ,sheep ,cattle ,livestock ,analgesia ,production animals ,Veterinary medicine ,SF600-1100 ,Zoology ,QL1-991 - Abstract
In veterinary medicine and livestock production, ensuring good animal husbandry is vital for the physical and emotional wellbeing of animals under our care. Pain poses challenges for assessment and mitigation, especially in species unable to express pain overtly. This review examines current pain mitigation interventions in routine husbandry, focuses on the duration of pain after procedures and implications for animal welfare. Pain behaviours have been observed for days or weeks after regular husbandry procedures, and many studies have noted pain-related behaviour persisting until study finalisation, suggesting potential undocumented pain beyond study completion. Current products registered in Australia for pain mitigation in livestock primarily target immediate pain associated with procedures. The future of pain relief in livestock demands longer-acting solutions to address post-procedural pain adequately. Providing pain relief for at least 72 h post surgery is recommended, but current products require retreatment intervals to achieve this, posing practical challenges, especially in livestock. Methods of pain relief provision, such as voluntary consumption of medicated feed, transdermal medication delivery and long-acting formulations offer potential solutions for prolonged pain relief, with research ongoing in these areas. There is a need for further research and development of longer-acting pain relief to ensure optimal welfare of livestock.
- Published
- 2024
- Full Text
- View/download PDF
36. Mortality Among Persons Entering HIV Care Compared With the General U.S. Population : An Observational Study.
- Author
-
Edwards, Jessie K, Cole, Stephen R, Breger, Tiffany L, Rudolph, Jacqueline E, Filiatreau, Lindsey M, Buchacz, Kate, Humes, Elizabeth, Rebeiro, Peter F, D'Souza, Gypsyamber, Gill, M John, Silverberg, Michael J, Mathews, W Christopher, Horberg, Michael A, Thorne, Jennifer, Hall, H Irene, Justice, Amy, Marconi, Vincent C, Lima, Viviane D, Bosch, Ronald J, Sterling, Timothy R, Althoff, Keri N, Moore, Richard D, Saag, Michael, and Eron, Joseph J
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Behavioral and Social Science ,Infectious Diseases ,Sexually Transmitted Infections ,HIV/AIDS ,Aetiology ,2.4 Surveillance and distribution ,Infection ,Good Health and Well Being ,Adult ,Cause of Death ,Cohort Studies ,Female ,HIV Infections ,Humans ,Male ,Middle Aged ,Population Surveillance ,Risk Factors ,United States ,Public Health and Health Services - Abstract
BackgroundUnderstanding advances in the care and treatment of adults with HIV as well as remaining gaps requires comparing differences in mortality between persons entering care for HIV and the general population.ObjectiveTo assess the extent to which mortality among persons entering HIV care in the United States is elevated over mortality among matched persons in the general U.S. population and trends in this difference over time.DesignObservational cohort study.SettingThirteen sites from the U.S. North American AIDS Cohort Collaboration on Research and Design.Participants82 766 adults entering HIV clinical care between 1999 and 2017 and a subset of the U.S. population matched on calendar time, age, sex, race/ethnicity, and county using U.S. mortality and population data compiled by the National Center for Health Statistics.MeasurementsFive-year all-cause mortality, estimated using the Kaplan-Meier estimator of the survival function.ResultsOverall 5-year mortality among persons entering HIV care was 10.6%, and mortality among the matched U.S. population was 2.9%, for a difference of 7.7 (95% CI, 7.4 to 7.9) percentage points. This difference decreased over time, from 11.1 percentage points among those entering care between 1999 and 2004 to 2.7 percentage points among those entering care between 2011 and 2017.LimitationMatching on available covariates may have failed to account for differences in mortality that were due to sociodemographic factors rather than consequences of HIV infection and other modifiable factors.ConclusionMortality among persons entering HIV care decreased dramatically between 1999 and 2017, although those entering care remained at modestly higher risk for death in the years after starting care than comparable persons in the general U.S. population.Primary funding sourceNational Institutes of Health.
- Published
- 2021
37. Current and Past Immunodeficiency Are Associated With Higher Hospitalization Rates Among Persons on Virologically Suppressive Antiretroviral Therapy for up to 11 Years
- Author
-
Davy-Mendez, Thibaut, Napravnik, Sonia, Eron, Joseph J, Cole, Stephen R, van Duin, David, Wohl, David A, Hogan, Brenna C, Althoff, Keri N, Gebo, Kelly A, Moore, Richard D, Silverberg, Michael J, Horberg, Michael A, Gill, M John, Mathews, W Christopher, Klein, Marina B, Colasanti, Jonathan A, Sterling, Timothy R, Mayor, Angel M, Rebeiro, Peter F, Buchacz, Kate, Li, Jun, Nanditha, Ni Gusti Ayu, Thorne, Jennifer E, Nijhawan, Ank, Berry, Stephen A, Benson, Constance A, Bosch, Ronald J, Kirk, Gregory D, Mayer, Kenneth H, Grasso, Chris, Hogg, Robert S, Montaner, Julio SG, Salters, Kate, Lima, Viviane D, Sereda, Paul, Trigg, Jason, Rodriguez, Benigno, Brown, Todd, Tien, Phyllis, D’Souza, Gypsyamber, Rabkin, Charles, Kroch, Abigail, Burchell, Ann, Betts, Adrian, Lindsay, oanne, Hunter-Mellado, Robert F, Martin, Jeffrey N, Brooks, John T, Saag, Michael S, Mugavero, Michael J, Willig, James, Mathews, William C, Kitahata, Mari M, Crane, Heidi M, Haas, David, Rebeiro, Peter, Turner, Megan, Tate, Janet, Dubrow, Robert, Fiellin, David, Gange, Stephen J, McKaig, Rosemary G, Freeman, Aimee M, Van Rompaey, Stephen E, Morton, Liz, McReynolds, Justin, Lober, William B, Lee, Jennifer S, You, Bin, Hogan, Brenna, Zhang, Jinbing, and Jing, Jerry
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Infectious Diseases ,Sexually Transmitted Infections ,Clinical Research ,Anti-HIV Agents ,CD4 Lymphocyte Count ,Canada ,Cohort Studies ,Female ,HIV Infections ,Hospitalization ,Humans ,Male ,Viral Load ,HIV/AIDS ,6.1 Pharmaceuticals ,HIV ,hospitalization ,CD4 lymphocyte count ,sustained virologic response ,cohort studies ,North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA ,Biological Sciences ,Medical and Health Sciences ,Microbiology ,Biological sciences ,Biomedical and clinical sciences ,Health sciences - Abstract
BackgroundPersons with HIV (PWH) with persistently low CD4 counts despite efficacious antiretroviral therapy could have higher hospitalization risk.MethodsIn six US and Canadian clinical cohorts, PWH with virologic suppression for ≥1 year in 2005-2015 were followed until virologic failure, loss to follow-up, death, or study end. Stratified by early (Years 2-5) and long-term (Years 6-11) suppression and lowest pre-suppression CD4 count 500 cells/μL had an aIRR of 1.44 during early suppression (95% CI 1.01-2.06), and 1.67 (1.03-2.72) during long-term suppression. Among patients with lowest pre-suppression CD4 ≥200 (56%), patients with current CD4 351-500 versus >500 cells/μL had an aIRR of 1.22 (0.93-1.60) during early suppression and 2.09 (1.18-3.70) during long-term suppression.ConclusionsVirologically suppressed patients with lower CD4 counts experienced higher hospitalization rates, and could potentially benefit from targeted clinical management strategies.
- Published
- 2021
38. Indoleamine 2,3 dioxygenase, age, and immune activation in people living with HIV
- Author
-
Baer, Stephanie L, Colombo, Rhonda E, Johnson, Maribeth H, Wakade, Sushama, Pacholczyk, Gabriela, Newman-Whitlow, Cheryl, Thompson, Stuart A, Saag, Michael S, Martin, Jeffrey N, Floris-Moore, Michelle, Huang, Lei, and Mellor, Andrew L
- Subjects
Biomedical and Clinical Sciences ,Immunology ,Infectious Diseases ,Aging ,Sexually Transmitted Infections ,HIV/AIDS ,Infection ,Bacterial Translocation ,Case-Control Studies ,Cohort Studies ,HIV Infections ,Humans ,Indoleamine-Pyrrole 2 ,3 ,-Dioxygenase ,Lipopolysaccharides ,Neopterin ,aging ,immune tolerance ,inflammation ,Clinical Sciences ,General Clinical Medicine ,Clinical sciences - Abstract
Immune activation complicates HIV despite antiretroviral therapy (ART). Indoleamine 2,3 dioxygenase (IDO) catabolizes tryptophan (T) to kynurenine (K), regulating immune activity, and IDO activity increases with age. This study examines the relationship of IDO activity, bacterial translocation, and aging in people living with HIV (PLWH) on ART. Samples and data from PLWH on ART from the Centers for AIDS Research Network of Integrated Clinical Systems and from matched HIV-uninfected patients (controls) from the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study were analyzed. The ratio of K to T (K:T) and neopterin were indicators of inflammation; 16S ribosomal DNA (16S rDNA) and lipopolysaccharide (LPS) were markers of bacterial translocation. Samples and data from 205 PLWH and 99 controls were analyzed. PLWH had higher K:T values across all ages, with a significant relationship between age and K:T for both groups. CD4 count or CD4 nadir had no association with K:T. There was no positive association between level of 16S rDNA or LPS detection and K:T. K:T and neopterin were associated. PLWH had elevated IDO activity, at younger ages, despite ART. This study suggests K:T ratio increases with age in both groups and is elevated in PLWH at all ages compared with age-matched controls.
- Published
- 2021
39. Dental Students’ and Dental School Graduates’ Practical Skills: An International Survey of Perceptions of National Dental Associations in Europe.
- Author
-
Gerhard Wolf, Thomas, Dianišková, Simona, Cavallé, Edoardo, Aliyeva, Rena, Cagetti, Maria-Grazia, Campus, Guglielmo, Deschner, James, Forna, Norina, Ilhan, Duygu, Mazevet, Marco, Lella, Anna, Melo, Paulo, Perlea, Paula, Rovera, Angela, Sculean, Anton, Sharkov, Nikolai, Slutsky, Ariel, Roma Torres, António, and Saag, Mare
- Subjects
DENTAL students ,DENTAL schools ,GRADUATE education ,DENTAL education ,PRACTICE of dentistry ,REGIONALISM (International organization) ,GRADUATE students - Abstract
Purpose: Dental students learn knowledge and practical skills to provide oral health care to the population. Practical skills must be maintained or continuously developed throughout a professional career. This cross-sectional survey aimed to evaluate the perception of practical skills of dental students and dental-school graduates by national dental associations (NDAs) in international comparison in the European Regional Organization of the FDI World Dental Federation (ERO-FDI) zone. Materials and Methods: A questionnaire of 14 items collected information on pre-/postgraduate areas. Results: A total of 25 countries participated (response rate: 69.4%), with 80.0% having minimum requirements for practical skills acquisition and 64.0% starting practical training in the 3rd year of study. In countries where clinical practical work on patients begins in the 2nd year of study, practical skills of graduates are perceived as average, starting in the 3rd year of study as mainly good, starting in the 4th as varying widely from poor to very good. In total, 76.0% of respondents feel that improvements are needed before entering dental practice. Improvements could be reached by treating more patients in dental school (32.0%), increasing the quantity of clinical training (20.0%), or having more clinical instructors (12.0%). In 56.0% of the countries, it is possible to open one’s own dental practice immediately after graduation, and in 16.0%, prior vocational training is mandatory. Conclusions: All participating countries in the ERO-FDI zone reported practical training in dental school, most starting in the 3rd year of study. The perception of practical skills of dental students and dental-school graduates among NDAs is very hetero geneous. Reasons for the perceived deficiencies should be further explored. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. Hospitalization Rates and Causes Among Persons With HIV in the United States and Canada, 2005–2015
- Author
-
Davy-Mendez, Thibaut, Napravnik, Sonia, Hogan, Brenna C, Althoff, Keri N, Gebo, Kelly A, Moore, Richard D, Horberg, Michael A, Silverberg, Michael J, Gill, M John, Crane, Heidi M, Marconi, Vincent C, Bosch, Ronald J, Colasanti, Jonathan A, Sterling, Timothy R, Mathews, W Christopher, Mayor, Angel M, Nanditha, Ni Gusti Ayu, Buchacz, Kate, Li, Jun, Rebeiro, Peter F, Thorne, Jennifer E, Nijhawan, Ank, van Duin, David, Wohl, David A, Eron, Joseph J, Berry, Stephen A, Benson, Constance A, Kirk, Gregory D, Mayer, Kenneth H, Grasso, Chris, Hogg, Robert S, Harrigan, P Richard, Montaner, Julio SG, Yip, Benita, Zhu, Julia, Salters, Kate, Gabler, Karyn, Carey, John T, Rodriguez, Benigno, Brown, Todd, Tien, Phyllis, D’Souza, Gypsyamber, Rabkin, Charles, Klein, Marina B, Kroch, Abigail, Burchell, Ann, Betts, Adrian, Lindsay, Joanne, Hunter-Mellado, Robert F, Martin, Jeffrey N, Brooks, John T, Saag, Michael S, Mugavero, Michael J, Willig, James, Mathews, William C, Kitahata, Mari M, Haas, David, Rebeiro, Peter, Turner, Megan, Tate, Janet, Dubrow, Robert, Fiellin, David, Gange, Stephen J, McKaig, Rosemary G, Freeman, Aimee M, Van Rompaey, Stephen E, Morton, Liz, McReynolds, Justin, Lober, William B, Lee, Jennifer S, and You, Bin
- Subjects
Biomedical and Clinical Sciences ,Public Health ,Health Sciences ,Clinical Sciences ,Medical Microbiology ,Sexually Transmitted Infections ,Aging ,Infectious Diseases ,Prevention ,HIV/AIDS ,Infection ,Good Health and Well Being ,Acquired Immunodeficiency Syndrome ,Anti-HIV Agents ,CD4 Lymphocyte Count ,Canada ,Comorbidity ,HIV Infections ,Hospitalization ,Humans ,Risk Factors ,United States ,Viral Load ,HIV ,hospitalization ,cohort studies ,North American AIDS Cohort Collaboration on Research and Design of IeDEA ,Biological Sciences ,Medical and Health Sciences ,Microbiology ,Biological sciences ,Biomedical and clinical sciences ,Health sciences - Abstract
BackgroundTo assess the possible impact of antiretroviral therapy improvements, aging, and comorbidities, we examined trends in all-cause and cause-specific hospitalization rates among persons with HIV (PWH) from 2005 to 2015.MethodsIn 6 clinical cohorts, we followed PWH in care (≥1 outpatient CD4 count or HIV load [VL] every 12 months) and categorized ICD codes of primary discharge diagnoses using modified Clinical Classifications Software. Poisson regression estimated hospitalization rate ratios for calendar time trends, adjusted for demographics, HIV risk factor, and annually updated age, CD4, and VL.ResultsAmong 28 057 patients (125 724 person-years), from 2005 to 2015, the median CD4 increased from 389 to 580 cells/µL and virologic suppression from 55% to 85% of patients. Unadjusted all-cause hospitalization rates decreased from 22.3 per 100 person-years in 2005 (95% confidence interval [CI], 20.6-24.1) to 13.0 in 2015 (95% CI, 12.2-14.0). Unadjusted rates decreased for almost all diagnostic categories. Adjusted rates decreased for all-cause, cardiovascular, and AIDS-defining conditions, increased for non-AIDS-defining infection, and were stable for most other categories.ConclusionsAmong PWH with increasing CD4 counts and viral suppression, unadjusted hospitalization rates decreased for all-cause and most cause-specific hospitalizations, despite the potential effects of aging, comorbidities, and cumulative exposure to HIV and antiretrovirals.
- Published
- 2021
41. Timing of Antiretroviral Therapy Initiation and Risk of Cancer Among Persons Living With Human Immunodeficiency Virus
- Author
-
Silverberg, Michael J, Leyden, Wendy, Hernández-Ramírez, Raúl U, Qin, Li, Lin, Haiqun, Justice, Amy C, Hessol, Nancy A, Achenbach, Chad J, D’Souza, Gypsyamber, Engels, Eric A, Althoff, Keri N, Mayor, Angel M, Sterling, Timothy R, Kitahata, Mari M, Bosch, Ronald J, Saag, Michael S, Rabkin, Charles S, Horberg, Michael A, Gill, M John, Grover, Surbhi, Mathews, W Christopher, Li, Jun, Crane, Heidi M, Gange, Stephen J, Lau, Bryan, Moore, Richard D, Dubrow, Robert, and Neugebauer, Romain S
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Hematology ,Sexually Transmitted Infections ,HIV/AIDS ,Lymphatic Research ,Prevention ,Emerging Infectious Diseases ,Clinical Research ,Infectious Diseases ,Health Disparities ,Cancer ,Rare Diseases ,Minority Health ,Lymphoma ,Women's Health ,Infection ,Good Health and Well Being ,Acquired Immunodeficiency Syndrome ,CD4 Lymphocyte Count ,HIV ,HIV Infections ,Humans ,Neoplasms ,Sarcoma ,Kaposi ,cancer ,epidemiology ,antiretroviral therapy ,causal inference ,Biological Sciences ,Medical and Health Sciences ,Microbiology ,Clinical sciences - Abstract
BackgroundPersons living with human immunodeficiency virus (HIV; PLWH) experience a high burden of cancer. It remains unknown which cancer types are reduced in PLWH with earlier initiation of antiretroviral therapy (ART).MethodsWe evaluated AIDS-free, ART-naive PLWH during 1996-2014 from 22 cohorts participating in the North American AIDS Cohort Collaboration on Research and Design. PLWH were followed from first observed CD4 of 350-500 cells/µL (baseline) until incident cancer, death, lost-to-follow-up, or December 2014. Outcomes included 6 cancer groups and 5 individual cancers that were confirmed by chart review or cancer registry linkage. We evaluated the effect of earlier (in the first 6 months after baseline) versus deferred ART initiation on cancer risk. Marginal structural models were used with inverse probability weighting to account for time-dependent confounding and informative right-censoring, with weights informed by subject's age, sex, cohort, baseline year, race/ethnicity, HIV transmission risk, smoking, viral hepatitis, CD4, and AIDS diagnoses.ResultsProtective results for earlier ART were found for any cancer (adjusted hazard ratio [HR] 0.57; 95% confidence interval [CI], .37-.86), AIDS-defining cancers (HR 0.23; 95% CI, .11-.49), any virus-related cancer (HR 0.30; 95% CI, .16-.54), Kaposi sarcoma (HR 0.25; 95% CI, .10-.61), and non-Hodgkin lymphoma (HR 0.22; 95% CI, .06-.73). By 15 years, there was also an observed reduced risk with earlier ART for virus-related NADCs (0.6% vs 2.3%; adjusted risk difference -1.6; 95% CI, -2.8, -.5).ConclusionsEarlier ART initiation has potential to reduce the burden of virus-related cancers in PLWH but not non-AIDS-defining cancers (NADCs) without known or suspected viral etiology.
- Published
- 2021
42. Real-world bone turnover marker use: impact on treatment decisions and fracture
- Author
-
Lane, NE, Saag, K, O’Neill, TJ, Manion, M, Shah, R, Klause, U, and Eastell, R
- Subjects
Aging ,Clinical Research ,Osteoporosis ,Musculoskeletal ,Aged ,Biomarkers ,Bone Density ,Bone Density Conservation Agents ,Bone Remodeling ,Fractures ,Bone ,Humans ,Medicare ,Retrospective Studies ,United States ,Biochemical markers ,Bone turnover ,Fracture risk ,Monitoring treatment ,Biomedical Engineering ,Clinical Sciences ,Public Health and Health Services ,Endocrinology & Metabolism - Abstract
The use of bone turnover marker (BTM) testing for patients with osteoporosis in the USA has not been well characterized. This retrospective US-based real-world data study found BTM testing has some association with treatment decision-making and lower fracture risk in patients with presumed osteoporosis, supporting its use in clinical practice.IntroductionThe purpose of this study was to characterize bone turnover marker (BTM) testing patterns and estimate their clinical utility in treatment decision-making and fragility fracture risk in patients with osteoporosis using a retrospective claims database.MethodsData from patients aged ≥ 50 years with newly diagnosed osteoporosis enrolled in the Truven MarketScan® Commercial Claims and Encounters and Medicare Supplemental and Co-ordination of Benefits databases from January 2008 to June 2018 were included. Osteoporosis was ascertained by explicit claims, fragility fracture events associated with osteoporosis, or prescribed anti-resorptive or anabolic therapy. BTM-tested patients were 1:1 propensity score matched to those untested following diagnosis. Generalized estimating equation models were performed to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for testing versus no testing on both treatment decision-making and fragility fracture.ResultsOf the 457,829 patients with osteoporosis, 6075 were identified with ≥ 1 BTM test following diagnosis; of these patients, 1345 had a unique treatment decision made ≤ 30 days from BTM testing. The percentage of patients receiving BTM tests increased significantly each year (average annual % change: + 8.1%; 95% CI: 5.6-9.0; p = 0.01). Patients tested were significantly more likely to have a treatment decision (OR: 1.14; 95% CI: 1.13-1.15), and testing was associated with lower odds of fracture versus those untested (OR: 0.87; 95% CI: 0.85-0.88).ConclusionIn this large, heterogeneous population of patients with presumed osteoporosis, BTM testing was associated with treatment decision-making, likely leading to fragility fracture reduction following use.
- Published
- 2021
43. HIV Viremia and Risk of Stroke Among People Living with HIV Who Are Using Antiretroviral Therapy.
- Author
-
Harding, Barbara N, Avoundjian, Tigran, Heckbert, Susan R, Whitney, Bridget M, Nance, Robin M, Ruderman, Stephanie A, Kalani, Rizwan, Tirschwell, David L, Ho, Emily L, Becker, Kyra J, Zunt, Joseph, Chow, Felicia, Huffer, Andrew, Mathews, W Christopher, Eron, Joseph, Moore, Richard D, Marra, Christina M, Burkholder, Greer, Saag, Michael S, Kitahata, Mari M, Crane, Heidi M, and Delaney, Joseph C
- Subjects
Humans ,Viremia ,HIV Infections ,Anti-HIV Agents ,Antiretroviral Therapy ,Highly Active ,Viral Load ,United States ,Stroke ,HIV/AIDS ,Clinical Research ,Brain Disorders ,Rehabilitation ,Infectious Diseases ,Infection ,HIV ,viremia ,viral load ,stroke ,ischemic stroke ,hemorrhagic stroke ,Statistics ,Public Health and Health Services ,Epidemiology - Abstract
BackgroundRates of stroke are higher in people living with HIV compared with age-matched uninfected individuals. Causes of elevated stroke risk, including the role of viremia, are poorly defined.MethodsBetween 1 January 2006 and 31 December 2014, we identified incident strokes among people living with HIV on antiretroviral therapy at five sites across the United States. We considered three parameterizations of viral load (VL) including (1) baseline (most recent VL before study entry), (2) time-updated, and (3) cumulative VL (copy-days/mL of virus). We used Cox proportional hazards models to estimate hazard ratios (HRs) for stroke risk comparing the 75th percentile ("high VL") to the 25th percentile ("low VL") of baseline and time-updated VL. We used marginal structural Cox models, with most models adjusted for traditional stroke risk factors, to estimate HRs for stroke associated with cumulative VL.ResultsAmong 15,974 people living with HIV, 139 experienced a stroke (113 ischemic; 18 hemorrhagic; eight were unknown type) over a median follow-up of 4.2 years. Median baseline VL was 38 copies/mL (interquartile interval: 24, 3,420). High baseline VL was associated with increased risk of both ischemic (HR: 1.3; 95% CI = 0.96-1.7) and hemorrhagic stroke (HR: 3.1; 95% CI = 1.6-5.9). In time-updated models, high VL was also associated with an increased risk of any stroke (HR: 1.8; 95% CI = 1.4-2.3). We observed no association between cumulative VL and stroke risk.ConclusionsOur findings are consistent with the hypothesis that elevated HIV VL may increase stroke risk, regardless of previous VL levels.
- Published
- 2021
44. Designing a Strategy Trial for the Management of Gout: The Use of a Modified Delphi Panel
- Author
-
Solomon, Daniel H, Weissman, Joel S, Choi, Hyon, Atlas, Steven J, Berardinelli, Cesar, Dedier, Julien, Fischer, Michael A, Fitzgerald, John, Hinteregger, Erica, Johnsen, Brianne, Marini, Diana D, McLean, Robert, Murray, Fred, Neogi, Tuhina, Oertel, Lynn B, Pillinger, Michael H, Riggs, Kevin R, Saag, Ken, Suh, Dong, Watkins, James, and Barry, Michael J
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Clinical sciences - Abstract
ObjectiveDisagreement exists between rheumatology and primary care societies regarding gout management. This paper describes a formal process for gathering input from stakeholders in the planning of a trial to compare gout management strategies.MethodsWe recruited patients, nurses, physician assistants, primary care clinicians, and rheumatologists to participate in a modified Delphi panel (mDP) to provide input on design of a trial focused on optimal management for primary care patients with gout. The 16 panelists received a plain-language briefing document that discussed the rationale for the trial, key clinical issues in gout, and aspects of trial design. The panelists also received information and considerations on nine voting questions (VQs), judged to be the key design questions. Cognitive interviews with panelists ensured that the VQs were understood by the range of panelists involved in the mDP. Panelists were asked to score all VQs from 1 (definitely no) to 9 (definitely yes). Two voting rounds were conducted-round 1 by email and round 2 by video conference.ResultsThe VQs were modified through the cognitive interviews. The round 1 voting resulted in consensus on eight items, with consensus defined as median voting score in the same tercile (1-3, 4-6 or 7-9). Re-voting at the meeting (round 2) reached consensus on the remaining item.ConclusionAn mDP with various stakeholders facilitated consensus on the design of a trial of different management strategies for chronic gout. This method may be useful for designing trials of clinical questions with substantial disagreement across stakeholders.
- Published
- 2021
45. Types of Stroke Among People Living With HIV in the United States.
- Author
-
Crane, Heidi M, Nance, Robin M, Avoundjian, Tigran, Harding, Barbara N, Whitney, Bridget M, Chow, Felicia C, Becker, Kyra J, Marra, Christina M, Zunt, Joseph R, Ho, Emily L, Kalani, Rizwan, Huffer, Andrew, Burkholder, Greer A, Willig, Amanda L, Moore, Richard D, Mathews, William C, Eron, Joseph J, Napravnik, Sonia, Lober, William B, Barnes, Greg S, McReynolds, Justin, Feinstein, Matthew J, Heckbert, Susan R, Saag, Michael S, Kitahata, Mari M, Delaney, Joseph AC, and Tirschwell, David L
- Subjects
Brain Disorders ,Clinical Research ,Neurosciences ,HIV/AIDS ,Infectious Diseases ,Stroke ,Prevention ,Good Health and Well Being ,Adult ,Atherosclerosis ,CD4 Lymphocyte Count ,Cohort Studies ,Female ,HIV Infections ,Humans ,Hypertension ,Male ,Middle Aged ,Risk Factors ,United States ,HIV ,stroke ,ischemic stroke ,hemorrhagic stroke ,stroke subtypes ,Clinical Sciences ,Public Health and Health Services ,Virology - Abstract
BackgroundMost studies of stroke in people living with HIV (PLWH) do not use verified stroke diagnoses, are small, and/or do not differentiate stroke types and subtypes.SettingCNICS, a U.S. multisite clinical cohort of PLWH in care.MethodsWe implemented a centralized adjudication stroke protocol to identify stroke type, subtype, and precipitating conditions identified as direct causes including infection and illicit drug use in a large diverse HIV cohort.ResultsAmong 26,514 PLWH, there were 401 strokes, 75% of which were ischemic. Precipitating factors such as sepsis or same-day cocaine use were identified in 40% of ischemic strokes. Those with precipitating factors were younger, had more severe HIV disease, and fewer traditional stroke risk factors such as diabetes and hypertension. Ischemic stroke subtypes included cardioembolic (20%), large vessel atherosclerosis (13%), and small vessel (24%) ischemic strokes. Individuals with small vessel strokes were older, were more likely to have a higher current CD4 cell count than those with cardioembolic strokes and had the highest mean blood pressure of the ischemic stroke subtypes.ConclusionIschemic stroke, particularly small vessel and cardioembolic subtypes, were the most common strokes among PLWH. Traditional and HIV-related risk factors differed by stroke type/subtype. Precipitating factors including infections and drug use were common. These results suggest that there may be different biological phenomena occurring among PLWH and that understanding HIV-related and traditional risk factors and in particular precipitating factors for each type/subtype may be key to understanding, and therefore preventing, strokes among PLWH.
- Published
- 2021
46. Correction to: Real-world bone turnover marker use: impact on treatment decisions and fracture
- Author
-
Lane, NE, Saag, K, O’Neill, TJ, Manion, M, Shah, R, Klause, U, and Eastell, R
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Biomedical Engineering ,Public Health and Health Services ,Endocrinology & Metabolism ,Clinical sciences ,Epidemiology - Abstract
The article “Real-world bone turnover marker use: impact on treatment decisions and fracture”, written by N. E. Lane, K. Saag, T. J. O’Neill, M. Manion, R. Shah, U. Klause and R. Eastell was originally published electronically on the publisher’s internet portal on 24. November 2020 without open access. With the author(s)’ decision to opt for Open Choice the copyright of the article changed on 18. December 2020 to © The Author(s) 2020 and the article is forthwith distributed under a Creative Commons Attribution this article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. The original article has been corrected.
- Published
- 2021
47. Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era.
- Author
-
Ruderman, Stephanie A, Crane, Heidi M, Nance, Robin M, Whitney, Bridget M, Harding, Barbara N, Mayer, Kenneth H, Moore, Richard D, Eron, Joseph J, Geng, Elvin, Mathews, William C, Rodriguez, B, Willig, Amanda L, Burkholder, Greer A, Lindström, Sara, Wood, Brian R, Collier, Ann C, Vannappagari, Vani, Henegar, Cassidy, Van Wyk, Jean, Curtis, Lloyd, Saag, Michael S, Kitahata, Mari M, and Delaney, Joseph AC
- Subjects
Clinical Research ,HIV/AIDS ,Clinical Trials and Supportive Activities ,Prevention ,Infectious Diseases ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Good Health and Well Being ,Adult ,Alanine ,Alkynes ,Anti-HIV Agents ,Anti-Retroviral Agents ,Benzoxazines ,Cyclopropanes ,Dideoxynucleosides ,Female ,HIV Infections ,HIV Integrase Inhibitors ,Heterocyclic Compounds ,3-Ring ,Humans ,Male ,Middle Aged ,Oxazines ,Piperazines ,Pyridones ,Tenofovir ,Weight Gain ,HIV ,weight ,antiretroviral therapy ,integrase strand transfer inhibitors ,dolutegravir ,bictegravir ,Clinical Sciences ,Public Health and Health Services ,Virology - Abstract
ObjectivesEvaluate differences in weight change by regimen among people living with HIV (PLWH) initiating antiretroviral therapy (ART) in the current era.MethodsBetween 2012 and 2019, 3232 ART-naïve PLWH initiated ≥3-drug ART regimens in 8 Centers for AIDS Research Network of Integrated Clinical Systems sites. We estimated weight change by regimen for 11 regimens in the immediate (first 6 months) and extended (all follow-up on initial regimen) periods using linear mixed models adjusted for time on regimen, interaction between time and regimen, age, sex, race/ethnicity, hepatitis B/C coinfection, nadir CD4, smoking, diabetes, antipsychotic medication, and site. We included more recently approved regimens [eg, with tenofovir alafenamide fumarate (TAF)] only in the immediate period analyses to ensure comparable follow-up time.ResultsMean follow-up was 1.9 years on initial ART regimen. In comparison to efavirenz/tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC), initiating bictegravir/TAF/FTC {3.9 kg [95% confidence interval (CI): 2.2 to 5.5]} and dolutegravir/TAF/FTC [4.4 kg (95% CI: 2.1 to 6.6)] were associated with the greatest weight gain in the immediate period, followed by darunavir/TDF/FTC [3.7 kg (95% CI: 2.1 to 5.2)] and dolutegravir/TDF/FTC [2.6 kg (95% CI: 1.3 to 3.9)]. In the extended period, compared with efavirenz/TDF/FTC, initiating darunavir/TDF/FTC was associated with a 1.0 kg (95% CI: 0.5 to 1.5) per 6-months greater weight gain, whereas dolutegravir/abacavir/FTC was associated with a 0.6-kg (95% CI: 0.3 to 0.9) and dolutegravir/TDF/FTC was associated with a 0.6-kg (95% CI: 0.1 to 1.1) per 6-months greater gain. Weight gain on dolutegravir/abacavir/FTC and darunavir/TDF/FTC was significantly greater than that for several integrase inhibitor-based regimens.ConclusionsThere is heterogeneity between regimens in weight gain following ART initiation among previously ART-naïve PLWH; we observed greater gain among PLWH taking newer integrase strand transfer inhibitors (DTG, BIC) and DRV-based regimens.
- Published
- 2021
48. Brief Report: Differences in Types of Myocardial Infarctions Among People Aging With HIV.
- Author
-
Crane, Heidi M, Nance, Robin M, Whitney, Bridget M, Heckbert, Susan R, Budoff, Matthew, High, Kevin, Landay, Alan, Feinstein, Matthew, Moore, Richard D, Mathews, William Christopher, Christopoulos, Katerina, Saag, Michael S, Willig, Amanda, Eron, Joseph J, Kitahata, Mari M, and Delaney, Joseph AC
- Subjects
Aging ,HIV/AIDS ,Cardiovascular ,Infectious Diseases ,Good Health and Well Being ,Adult ,Aged ,Cohort Studies ,Female ,HIV Infections ,Humans ,Incidence ,Longitudinal Studies ,Male ,Middle Aged ,Myocardial Infarction ,Plaque ,Atherosclerotic ,myocardial infarction ,type 1 MI ,type 2 MI ,aging ,HIV ,Centers for AIDS Research Network of Clinical Information Systems ,Clinical Sciences ,Public Health and Health Services ,Virology - Abstract
BackgroundType 1 myocardial infarctions (T1MIs) result from atherosclerotic plaque instability, rupture, and/or erosion. Type 2 MIs (T2MIs) are secondary to causes such as sepsis and cocaine-induced vasospasm resulting in an oxygen demand-supply mismatch and are associated with higher mortality than T1MIs. T2MIs account for a higher proportion of MIs among people living with HIV (PLWH) compared with the general population. We compared MI rates by type among aging PLWH. We hypothesized that increases in MI rates with older age would differ by MI types, and T2MIs would be more common than T1MIs in younger individuals.MethodsPotential MIs from 6 sites were centrally adjudicated using physician notes, electrocardiograms, procedure results, and laboratory results. Reviewers categorized MIs by type and identified causes of T2MIs. We calculated T1MI and T2MI incidence rates. Incidence rate ratios were calculated for T2MI vs. T1MI rates per decade of age.ResultsWe included 462 T1MIs (52%) and 413 T2MIs (48%). T1MI rates increased with older age, although T1MIs occurred in all age decades including young adults. T2MI rates were significantly higher than T1MI rates for PLWH younger than 40 years. T1MI rates were similar or higher than T2MI rates among those older than 40 years (significantly higher for those aged 50-59 and 60-69 years).ConclusionsRates of T2MIs were higher than T1MIs until age 40 years among PLWH, differing from the general population, but rates of both were high among older PLWH. Given prognostic differences between MI types, these results highlight the importance of differentiating MI types among PLWH.
- Published
- 2021
49. A mentor training workshop focused on fostering diversity engenders lasting impact on mentoring techniques: Results of a long-term evaluation
- Author
-
Johnson, Mallory O, Fuchs, Jonathan D, Sterling, Lauren, Sauceda, John A, Saag, Michael S, Fernandez, Alicia, Evans, Clyde H, and Gandhi, Monica
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Minority Health ,Health Disparities ,Mentoring ,diversity ,HIV ,AIDS ,HIV/AIDS - Abstract
IntroductionTrainees and investigators from underrepresented minority (URM) backgrounds face unique challenges to establishing successful careers in clinical and translational research. Structured training for mentors is an important mechanism to increase the diversity of the research workforce. This article presents data from an evaluation of the University of California, San Francisco (UCSF) Center for AIDS Research (CFAR) Mentoring the Mentors program aimed at improving mentors' competency in working with diverse mentees in HIV research.MethodsMentors from around the USA who had in one of seven separate 2-day training workshops conducted from 2013 to 2020 were invited to participate in an online evaluation survey of their experiences with the training and their subsequent mentoring activities.ResultsThere was a high response rate (80%) among the 226 mentors invited to complete the survey. The 180 respondents were diverse in demographics, professional disciplines, and geographic distribution. Quantitative and qualitative data indicate a lasting positive impact of the training, with sustained improvements documented on a validated measure of self-appraised mentoring competency. Respondents also endorsed high interest in future, follow-up training with continued focus on topics related to mentoring in the context of diversity.ConclusionThe evaluation of the UCSF CFAR Mentoring the Mentors program showed lasting impact in improving mentoring practices, coupled with high interest in continued in-depth training in areas focused on diversity, equity, and inclusion.
- Published
- 2021
50. Undertreatment of opioid use disorder in patients hospitalized with injection drug use-associated infections
- Author
-
Rosenthal, Elana S., Brokus, Christopher, Sun, Junfeng, Carpenter, Joseph E., Catalanotti, Jillian, Eaton, Ellen F., Steck, Alaina R., Kuo, Irene, Burkholder, Greer A., Akselrod, Hana, McGonigle, Keanan, Moran, Timothy, Mai, William, Notis, Melissa, Del Rio, Carlos, Greenberg, Alan, Saag, Michael S., Kottilil, Shyamasundaran, Masur, Henry, and Kattakuzhy, Sarah
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.